Rapt Therapeutics Starts Phase 2b Trial for Food Allergies
RAPT Therapeutics has opened enrollment for prestIgE, a randomized, double-blind, placebo-controlled Phase 2b study of ozureprubart (formerly RPT904) in...
eClinical Tech News
BridgeBio to Report Phase 3 Encaleret Results on Oct. 29
BridgeBio is set to release topline results from CALIBRATE, its Phase 3 study in autosomal dominant hypocalcemia type 1...
Wave’s Surging Obesity Drug Shows Promising Trial Results
Single-dose WVE-007 reduced circulating Activin E by 56% at 75 mg, 75% at 240 mg, and 85% at 400...
Wave Life Sciences Sees Positive Data for Obesity Drug WVE-007
Wave reported dose-dependent, single-dose reductions in circulating Activin E at day 29 in its INLIGHT obesity study: 85% at...
Tectonic’s TX45 Shows Positive Data in Phase 1b PH Trial
TX45 produced acute, directionally favorable hemodynamic and echocardiographic changes in PH-HFrEF after a single intravenous dose: pulmonary capillary wedge...
Immuron’s Latest Clinical Trial Update: A New Perspective
No new efficacy results were released. The Uniformed Services University Phase 2 traveler’s diarrhea field study of Travelan (n=851;...
Olema Presents Palazestrant OPERA-02 Trial at SABCS 2025
Olema will bring a trial‑in‑progress poster for its Phase 3 OPERA‑02 study to SABCS, detailing a randomized, double‑blind comparison...
Ultragenyx Doses First Patient in New Angelman Syndrome Study
Ultragenyx has fully randomized 129 patients aged 4–17 with full maternal UBE3A gene deletion in the global Phase 3...
FDA Grants Orphan Drug Status for Gastric Cancer Treatment
Dewpoint Therapeutics secured FDA Orphan Drug Designation for DPTX3186, an oral condensate modulator targeting the Wnt/β-catenin pathway in gastric...
gMG Biologics Expand in Early Treatment, Newcomers Challenge
Retention on first-line biologics in generalized myasthenia gravis sits at 90% in US practice, with Alexion’s Ultomiris and argenx’s...